Moderna Inc. confirmed on Monday that its coronavirus vaccine candidate is 94.1% efficient in stopping the virus and that it is estimated to direct regulators in the United States and Europe for an emergency use authorization (EUA) later today.
Chief Executive Stephane Bancel stated that “this positive primary analysis confirms the ability of our vaccine to prevent COVID-19 disease with 94.1% efficacy and importantly, the ability to prevent severe COVID-19 disease. We believe that our vaccine will provide a new and powerful tool that may change the course of this pandemic and help prevent severe disease, hospitalizations and death.”
The vaccine investigation conducted by the United States Food and Drug Administration (FDA) should continue a couple of weeks, Moderna estimated, remarking that an advisory board meeting will likely take place on December 17.
Historically, particularly over the so-called “Great Moderation” period (1990-2019) dominated by positive growth and low…
Solidarity with Gaza is apparent at universities around the globe, with student movements in France,…
The Ministry of the Interior declared, in an official press release, that security units in…
The prosecution at the Ariana Court of First Instance authorized agents of the Ariana North…
Labour's Sadiq Khan has won a third successive term as mayor of London. Khan defeated…
The civil society components of Al-Amra, in partnership with some organizations from the delegations of…
This website uses cookies.